Around 100,000 Australians live with myelofibrosis, which is a rare form of blood cancer. But an Australian-developed drug - just approved by the Therapeutic Goods Administration - is helping patients overcome some of the cancer's worst symptoms.
Key Points
- Myelofibrosis is a form of blood cancer which causes extensive scarring of the bone marrow, leading to low platelet production and increased risk of bleeding.
- Treating the condition is difficult - anaemia is a common side effect.
- A new drug, Momelotinib, approved by the Therapeutic Goods Administration in December, is giving patients hope.
Share
